HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Michel, R. B. Articles by Mattes, M. J. Search for Related Content PubMed PubMed Citation Articles by Michel, R. B. Articles by Mattes, M. J.

A Comparison of 4 Radionuclides Conjugated to Antibodies for Single-Cell Kill

¹ Center for Molecular Medicine and Immunology, Belleville, New Jersey
² National Institutes of Health, Bethesda, Maryland

We previously found that ⁶⁷Ga was more potent and more specific in single-cell kill than other Auger electron emitters and ß-particle emitters, using an anti-CD74 antibody (Ab) (major histocompatibility complex [MHC] class II invariant chain). Because anti-CD74 Abs follow an unusual processing pathway, with rapid delivery in very large amounts to lysosomes, it was important to determine if similar results would be obtained with other, more typical Abs. Methods: Target cells were Raji B-lymphoma cells, and the Abs tested were antimature MHC class II antigen (lacking the invariant chain) and anti-CD20, both of which react with high-density antigens. Labeling was with ¹²⁵I or ¹³¹I, by conventional iodination; with ¹¹¹In using the chelator benzyl-diethylenetriaminepentaacetic acid; or with ⁶⁷Ga using the chelator 1,4,7-triazacyclononane-1,4,7-triacetic acid. Abs were incubated with the cells for 2 d, uptake of radioactivity was assayed at various times, and toxicity was assayed primarily by a clonogenic assay. The fraction surviving was plotted versus cumulative disintegrations per cell to determine relative potency. Results: The ranking of the radionuclides for potency was ¹³¹I > ⁶⁷Ga > ¹²⁵I > ¹¹¹In. ⁶⁷Ga was approximately 2- to 3-fold more potent than ¹¹¹In. This was very similar to previous results with anti-CD74. Dosimetry calculations were generally consistent with the level of toxicity observed. In previous studies of nonspecific toxicity, the order of ranking was the same. Conclusion: The subcellular location of the bound Ab (whether on the cell surface or the cytoplasm) does not appear to be an important variable in the choice of radionuclide for single-cell kill. ⁶⁷Ga is a promising radionuclide for killing micrometastases, for high-density target antigens, but methods for achieving higher specific activity are required to fully exploit this approach. Each of the 4 radionuclides tested has certain advantages, and further studies are required to select the optimal radionuclide for a particular purpose.

Key Words: radioimmunotherapy • Auger electrons • micrometastases • CD20 • major histocompatibility complex class II

This article has been cited by other articles:

				L. Santoro, S. Boutaleb, V. Garambois, C. Bascoul-Mollevi, V. Boudousq, P.-O. Kotzki, M. Pelegrin, I. Navarro-Teulon, A. Pelegrin, and J.-P. Pouget Noninternalizing Monoclonal Antibodies Are Suitable Candidates for 125I Radioimmunotherapy of Small-Volume Peritoneal Carcinomatosis J. Nucl. Med., December 1, 2009; 50(12): 2033 - 2041. [Abstract] [Full Text] [PDF]

				R. M. Sharkey and D. M. Goldenberg Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates CA Cancer J Clin, July 1, 2006; 56(4): 226 - 243. [Abstract] [Full Text] [PDF]

				P. Chen, J. Wang, K. Hope, L. Jin, J. Dick, R. Cameron, J. Brandwein, M. Minden, and R. M. Reilly Nuclear Localizing Sequences Promote Nuclear Translocation and Enhance the Radiotoxicity of the Anti-CD33 Monoclonal Antibody HuM195 Labeled with 111In in Human Myeloid Leukemia Cells J. Nucl. Med., May 1, 2006; 47(5): 827 - 836. [Abstract] [Full Text] [PDF]

				M. Ginj, K. Hinni, S. Tschumi, S. Schulz, and H. R. Maecke Trifunctional Somatostatin-Based Derivatives Designed for Targeted Radiotherapy Using Auger Electron Emitters J. Nucl. Med., December 1, 2005; 46(12): 2097 - 2103. [Abstract] [Full Text] [PDF]

				R. B. Michel, P. M. Andrews, M. E. Castillo, and M. J. Mattes In vitro cytotoxicity of carcinoma cells with 111In-labeled antibodies to HER-2 Mol. Cancer Ther., June 1, 2005; 4(6): 927 - 937. [Abstract] [Full Text] [PDF]

				R. B. Michel, A. V. Rosario, P. M. Andrews, D. M. Goldenberg, and M. J. Mattes Therapy of Small Subcutaneous B-Lymphoma Xenografts with Antibodies Conjugated to Radionuclides Emitting Low-Energy Electrons Clin. Cancer Res., January 15, 2005; 11(2): 777 - 786. [Abstract] [Full Text] [PDF]

				R. B. Michel, M. E. Castillo, P. M. Andrews, and M. J. Mattes In vitro Toxicity of A-431 Carcinoma Cells with Antibodies to Epidermal Growth Factor Receptor and Epithelial Glycoprotein-1 Conjugated to Radionuclides Emitting Low-Energy Electrons Clin. Cancer Res., September 1, 2004; 10(17): 5957 - 5966. [Abstract] [Full Text] [PDF]